DANA-FARBER CANCER INSTITUTE

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Established: 1947-01-01

Employees: -

Market Cap: -

Website: http://www.dana-farber.org/

Clinical Trials

Symptom Management Implementation of Patient Reported Outcomes in Oncology

Not Applicable

Active, not recruiting

Conditions: Gynecologic Cancer
Gastrointestinal Cancer
Other Cancer
Thoracic Cancer

Interventions: Other: eSyM App Usage
Other: SASS Questionnaire

First Posted Date: 2019-02-22

Last Posted Date: 2025-01-09

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 25000

Registration Number: NCT03850912

Locations: 🇺🇸
Baptist Memoiral HealthCare, Memphis, Tennessee, United States
🇺🇸
Lifespan, Providence, Rhode Island, United States
🇺🇸
Maine Medical Center, Portland, Maine, United States

and more 3 locations

Tucatinib + Abemaciclib + Herceptin for HER2+ MBC

Phase 1

Withdrawn

Conditions: Breast Cancer

Interventions: Drug: Tucatinib
Drug: Abemaciclib
Drug: Trastuzumab
Drug: Aromatase Inhibitor

First Posted Date: 2019-02-19

Last Posted Date: 2020-10-23

Lead Sponsor: Dana-Farber Cancer Institute

Registration Number: NCT03846583

A Phase 2 Study of Mirvetuximab Soravtansine (IMGN853) and Pembrolizumab in Endometrial Cancer (EC)

Phase 2

Active, not recruiting

Conditions: Endometrial Cancer

Interventions: Drug: Pembrolizumab
Drug: IMGN853

First Posted Date: 2019-02-11

Last Posted Date: 2025-05-15

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 18

Registration Number: NCT03835819

Locations: 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Northwell Cancer Institute, Lake Success, New York, United States
🇺🇸
University of Massachusetts, Worcester, Massachusetts, United States

Yoga for Painful Chemotherapy-Induced Peripheral Neuropathy: A Pilot, Randomized-Controlled Study

Not Applicable

Completed

Conditions: Chronic Pain
Neuropathic Pain
Chemotherapy-induced Peripheral Neuropathy
Yoga

Interventions: Behavioral: Yoga

First Posted Date: 2019-01-31

Last Posted Date: 2022-03-28

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 47

Registration Number: NCT03824860

Locations: 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States

Elevate! : An Elderly Breast Cancer Cohort Study

Active, not recruiting

Conditions: Breast Cancer

Interventions: Behavioral: Observational cohort

First Posted Date: 2019-01-28

Last Posted Date: 2024-07-24

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 253

Registration Number: NCT03818087

Locations: 🇺🇸
Brigham and Women Hospital, Boston, Massachusetts, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Northern Light Cancer Care, Bangor, Maine, United States

and more 1 locations

NIMBUS: Nivolumab Plus Ipilimumab in Metastatic Hypermutated HER2-negative Breast Cancer

Phase 2

Active, not recruiting

Conditions: Breast Cancer

Interventions: Drug: Nivolumab
Drug: Ipilimumab

First Posted Date: 2018-12-28

Last Posted Date: 2025-02-26

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 30

Registration Number: NCT03789110

Locations: 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States
🇺🇸
University of Texas Southwestern Medical Center, Dallas, Texas, United States

Acupuncture for Hot Flashes in Hormone Receptor-Positive Breast Cancer, a Randomized Controlled Trial

Not Applicable

Active, not recruiting

Conditions: Breast Cancer

Interventions: Device: Acupuncture
Other: Usual Care

First Posted Date: 2018-12-21

Last Posted Date: 2025-05-04

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 84

Registration Number: NCT03783546

Locations: 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States

Conventional ADT w/ or w/Out Abiraterone Acetate + Prednisone and Apalutamide Following a Detectable PSA After Radiation and ADT

Phase 3

Terminated

Conditions: Prostate Cancer

Interventions: Drug: Prednisone
Drug: Apalutamide
Drug: Abiraterone Acetate
Drug: LHRH Agonist or Antagonist

First Posted Date: 2018-12-19

Last Posted Date: 2024-06-24

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 12

Registration Number: NCT03777982

Locations: 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States
🇺🇸
Dana-Farber/Brigham and Women's Cancer Center at Milford Regional Medical Center, Milford, Massachusetts, United States
🇺🇸
Dana-Farber/Brigham and Women's Cancer Center in clinical affiliation with South Shore Hospital, South Weymouth, Massachusetts, United States

and more 2 locations

A Feasibility Study of Durvalumab +/- Oleclumab as Neoadjuvant Therapy for Muscle-invasive Bladder Cancer (BLASST-2)

Phase 1

Completed

Conditions: Muscle Invasive Bladder Cancer

Interventions: Drug: Durvalumab
Drug: Oleclumab

First Posted Date: 2018-12-12

Last Posted Date: 2022-09-13

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 12

Registration Number: NCT03773666

Locations: 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States

GDC-0084 in Combination with Trastuzumab for Patients with HER2-Positive Breast Cancer Brain Metastases

Phase 2

Active, not recruiting

Conditions: Breast Cancer

Interventions: Drug: Trastuzumab
Drug: GDC-0084

First Posted Date: 2018-12-05

Last Posted Date: 2025-01-15

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 47

Registration Number: NCT03765983

Locations: 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

Home Terms & Conditions Privacy Policy